US 7,605,273 B2
Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
Alaric J. Dyckman, Lawrenceville, N.J. (US); Jagabandhu Das, Mercerville, N.J. (US); Katerina Leftheris, Skillman, N.J. (US); Chunjian Liu, Pennington, N.J. (US); Rulin Zhao, Pennington, N.J. (US); Bang-Chi Chen, Plainsboro, N.J. (US); and Stephen T. Wrobleski, Whitehouse Station, N.J. (US)
Assigned to Bristol-Myers Squibb Company, Princeton, N.J. (US)
Filed on May 12, 2008, as Appl. No. 12/118,794.
Application 12/118794 is a division of application No. 10/838129, filed on May 03, 2004, granted, now 7,396,935.
Claims priority of provisional application 60/467029, filed on May 01, 2003.
Prior Publication US 2008/0275092 A1, Nov. 06, 2008
Int. Cl. C07D 231/14 (2006.01)
U.S. Cl. 548—374.1 14 Claims
 
1. A compound having the formula (I),

OG Complex Work Unit Drawing
or a pharmaceutically-acceptable salt, or, stereoisomer thereof wherein:
Q is an optionally-substituted phenyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring;
R2 is selected from C1-6alkyl, NR7R8, and C1-6alkyl substituted with a group NR7R8;
R6 is C1-6alkyl or cyclopropyl;
R7 and R8 are independently selected from hydrogen, C1-6alkyl, and C3-6cycloalkyl, wherein each of said groups R7 and R8 are in turn optionally substituted with one to two of OH, O(C1-4alkyl), imidazolyl, pyridyl, phenyl, tetrahydrofuryl, NH2, NH(C1-4alkyl), N(C1-4alkyl)2, and N-morpholinyl, or alternatively, R7 and R8 are taken together with the nitrogen atom to which they are attached to form a morpholinyl, piperidinyl, or piperazinyl ring.